PC-10 antibody to proliferating cell nuclear antigen (PCNA) is not related to prognosis in human breast carcinoma.

G. Gasparini, S. Meli, F. Pozza, S. Cazzavillan, P. Bevilacqua

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The PC-10 monoclonal antibody to PCNA was employed to analyze proliferative grade in conventionally-formalin fixed, paraffin-embedded tumour samples of 162 patients with primary breast carcinoma. To perform the immunocytochemical method, sections were not heated, were de-waxed using alcohol, and then immersed in a phosphate-buffered saline solution and in methanol with 0.5% hydrogen peroxide to block endogenous peroxidase activity. Immunostaining was performed by a streptavidin-biotin peroxidase substrate. A semiquantitative scoring system was used to evaluate the fraction of nuclei that were PCNA-positive. The score ranged from 0% to 75% with a median value of 25%, mean of 27.8 +/- 1.5. PCNA staining was significantly associated with oestrogen receptor-negativity (p = 0.011) and correlated, but not at a statistically significant level, with tumour size (p = 0.08). No significant association was observed between PCNA and node status, grading, DNA ploidy, progesterone receptor or menopausal status. Prognostic indices such as number of positive lymph nodes and DNA ploidy were significantly associated with relapse-free survival (RFS) and overall survival (OS). No significant correlation between PCNA nuclear immunostaining and RFS or OS was observed after a median follow-up of 4 years. Our results indicate that analysis of PCNA alone does not seem to be a useful marker in identifying patients at different prognosis in human breast cancer.

Original languageEnglish
Pages (from-to)145-150
Number of pages6
JournalGrowth Regulation
Volume2
Issue number4
Publication statusPublished - Dec 1992

Fingerprint

Proliferating Cell Nuclear Antigen
Breast Neoplasms
Antibodies
Survival
Ploidies
Peroxidase
Recurrence
Streptavidin
DNA
Progesterone Receptors
Biotin
Sodium Chloride
Estrogen Receptors
Paraffin
Hydrogen Peroxide
Formaldehyde
Methanol
Neoplasms
Lymph Nodes
Phosphates

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Gasparini, G., Meli, S., Pozza, F., Cazzavillan, S., & Bevilacqua, P. (1992). PC-10 antibody to proliferating cell nuclear antigen (PCNA) is not related to prognosis in human breast carcinoma. Growth Regulation, 2(4), 145-150.

PC-10 antibody to proliferating cell nuclear antigen (PCNA) is not related to prognosis in human breast carcinoma. / Gasparini, G.; Meli, S.; Pozza, F.; Cazzavillan, S.; Bevilacqua, P.

In: Growth Regulation, Vol. 2, No. 4, 12.1992, p. 145-150.

Research output: Contribution to journalArticle

Gasparini, G, Meli, S, Pozza, F, Cazzavillan, S & Bevilacqua, P 1992, 'PC-10 antibody to proliferating cell nuclear antigen (PCNA) is not related to prognosis in human breast carcinoma.', Growth Regulation, vol. 2, no. 4, pp. 145-150.
Gasparini, G. ; Meli, S. ; Pozza, F. ; Cazzavillan, S. ; Bevilacqua, P. / PC-10 antibody to proliferating cell nuclear antigen (PCNA) is not related to prognosis in human breast carcinoma. In: Growth Regulation. 1992 ; Vol. 2, No. 4. pp. 145-150.
@article{04e9517e43da442dacf98e4ff6919803,
title = "PC-10 antibody to proliferating cell nuclear antigen (PCNA) is not related to prognosis in human breast carcinoma.",
abstract = "The PC-10 monoclonal antibody to PCNA was employed to analyze proliferative grade in conventionally-formalin fixed, paraffin-embedded tumour samples of 162 patients with primary breast carcinoma. To perform the immunocytochemical method, sections were not heated, were de-waxed using alcohol, and then immersed in a phosphate-buffered saline solution and in methanol with 0.5{\%} hydrogen peroxide to block endogenous peroxidase activity. Immunostaining was performed by a streptavidin-biotin peroxidase substrate. A semiquantitative scoring system was used to evaluate the fraction of nuclei that were PCNA-positive. The score ranged from 0{\%} to 75{\%} with a median value of 25{\%}, mean of 27.8 +/- 1.5. PCNA staining was significantly associated with oestrogen receptor-negativity (p = 0.011) and correlated, but not at a statistically significant level, with tumour size (p = 0.08). No significant association was observed between PCNA and node status, grading, DNA ploidy, progesterone receptor or menopausal status. Prognostic indices such as number of positive lymph nodes and DNA ploidy were significantly associated with relapse-free survival (RFS) and overall survival (OS). No significant correlation between PCNA nuclear immunostaining and RFS or OS was observed after a median follow-up of 4 years. Our results indicate that analysis of PCNA alone does not seem to be a useful marker in identifying patients at different prognosis in human breast cancer.",
author = "G. Gasparini and S. Meli and F. Pozza and S. Cazzavillan and P. Bevilacqua",
year = "1992",
month = "12",
language = "English",
volume = "2",
pages = "145--150",
journal = "Growth Regulation",
issn = "0956-523X",
publisher = "Churchill Livingstone",
number = "4",

}

TY - JOUR

T1 - PC-10 antibody to proliferating cell nuclear antigen (PCNA) is not related to prognosis in human breast carcinoma.

AU - Gasparini, G.

AU - Meli, S.

AU - Pozza, F.

AU - Cazzavillan, S.

AU - Bevilacqua, P.

PY - 1992/12

Y1 - 1992/12

N2 - The PC-10 monoclonal antibody to PCNA was employed to analyze proliferative grade in conventionally-formalin fixed, paraffin-embedded tumour samples of 162 patients with primary breast carcinoma. To perform the immunocytochemical method, sections were not heated, were de-waxed using alcohol, and then immersed in a phosphate-buffered saline solution and in methanol with 0.5% hydrogen peroxide to block endogenous peroxidase activity. Immunostaining was performed by a streptavidin-biotin peroxidase substrate. A semiquantitative scoring system was used to evaluate the fraction of nuclei that were PCNA-positive. The score ranged from 0% to 75% with a median value of 25%, mean of 27.8 +/- 1.5. PCNA staining was significantly associated with oestrogen receptor-negativity (p = 0.011) and correlated, but not at a statistically significant level, with tumour size (p = 0.08). No significant association was observed between PCNA and node status, grading, DNA ploidy, progesterone receptor or menopausal status. Prognostic indices such as number of positive lymph nodes and DNA ploidy were significantly associated with relapse-free survival (RFS) and overall survival (OS). No significant correlation between PCNA nuclear immunostaining and RFS or OS was observed after a median follow-up of 4 years. Our results indicate that analysis of PCNA alone does not seem to be a useful marker in identifying patients at different prognosis in human breast cancer.

AB - The PC-10 monoclonal antibody to PCNA was employed to analyze proliferative grade in conventionally-formalin fixed, paraffin-embedded tumour samples of 162 patients with primary breast carcinoma. To perform the immunocytochemical method, sections were not heated, were de-waxed using alcohol, and then immersed in a phosphate-buffered saline solution and in methanol with 0.5% hydrogen peroxide to block endogenous peroxidase activity. Immunostaining was performed by a streptavidin-biotin peroxidase substrate. A semiquantitative scoring system was used to evaluate the fraction of nuclei that were PCNA-positive. The score ranged from 0% to 75% with a median value of 25%, mean of 27.8 +/- 1.5. PCNA staining was significantly associated with oestrogen receptor-negativity (p = 0.011) and correlated, but not at a statistically significant level, with tumour size (p = 0.08). No significant association was observed between PCNA and node status, grading, DNA ploidy, progesterone receptor or menopausal status. Prognostic indices such as number of positive lymph nodes and DNA ploidy were significantly associated with relapse-free survival (RFS) and overall survival (OS). No significant correlation between PCNA nuclear immunostaining and RFS or OS was observed after a median follow-up of 4 years. Our results indicate that analysis of PCNA alone does not seem to be a useful marker in identifying patients at different prognosis in human breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0027026751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027026751&partnerID=8YFLogxK

M3 - Article

C2 - 1363282

AN - SCOPUS:0027026751

VL - 2

SP - 145

EP - 150

JO - Growth Regulation

JF - Growth Regulation

SN - 0956-523X

IS - 4

ER -